Roberto Caporali

May 23, 2024 | ard.bmj.com | Gerd R Burmester |Jacques-Eric Gottenberg |Roberto Caporali |Kevin L. Winthrop

Antirheumatic AgentsArthritis, RheumatoidTherapeuticsData availability statementData are available upon reasonable request. Anonymised individual patient data will be shared upon request for research purposes, dependent upon the nature of the request, the merit of the proposed research and the availability of the data and their intended use. The full data sharing policy for Gilead Sciences, Inc., can be found at https://www.gilead.com/about/ethics-and-code-of-conduct/policies.

Dec 14, 2023 | emjreviews.com | Roberto Caporali

Interview SummaryMethotrexate is a common first-line treatment for rheumatoid arthritis, yet its widespread and habitual usage often leads physicians to overlook the choice of administration route when planning management strategies. A recent survey involving 30 consultant rheumatologists from France, Germany, Italy, Poland, Spain, and the UK, identified variation in the utilisation and perceptions regarding oral versus subcutaneous delivery for methotrexate.